HPLC Method for Determination of Flunixin and Meglumine on Primesep 100
Separation type: Liquid Chromatography Mixed-mode
Flunixin is an analgesic and antypyretic nonsteroidal anti-inflammatory drug (NSAID) typically used by veterinarians in bovine and equine treatments. It is typically produced as a Meglumine salt, which helps stabilize and bulk up the medication in its solid form. Flunixin and Meglumine can be retained, separated, and analyzed on a Primesep 100 mixed-mode stationary phase column using an isocratic analytical method with a simple isocratic mobile phase of water, Acetonitrile (MeCN), and a sulfuric acid (H2SO4) buffer. This analysis method can be UV detected at 252 nm (Flunixin) with high resolution and peak symmetry and is compatible with Mass Spectrometry (MS), ELSD, and CAD (Flunixin and Melumine).
| Column | Primesep 100, 4.6×150 mm, 5 µm, 100A |
| Mobile Phase | MeCN – 60% |
| Buffer | TFA – 0.2% |
| Flow Rate | 1.0 ml/min |
| Detection | ELSD, 50C, UV 252 nm |
| Class of Compounds | Drug |
| Analyzing Compounds | Flunixin Meglumine |
Application Column
Primesep 100
The Primesep family of mixed-mode columns offers a wide variety of stationary phases, boasting unprecedented selectivity in the separation of a broad array of chemical compounds across multiple applications. Corresponding Primesep guard columns, available with all stationary phases, do not require holders. SIELC provides a method development service available to all customers. Inquire about our specially-tailored custom LC-phases for specific separations.
Select optionsMeglumine (N-Methyl-D-glucamine)
